Heart Test Laboratories announced that it has entered into a multi-year collaboration agreement with Rutgers University. HeartSciences and Rutgers will collaborate to develop AI-based ECG algorithms, which are expected to accelerate HeartSciences’ product development pipeline and further expand the clinical value of an ECG for low-cost detection of heart disease. These collaboration efforts will be focused on leveraging the extensive clinical data compiled at Rutgers. Andrew Simpson, CEO of HeartSciences, stated, "We are excited and honored to enter a collaboration with Dr. Sengupta and Rutgers University. Dr. Sengupta is a globally respected figure in the field of cardiology, including the application of technology to accelerate innovation in the field of cardiology. We have worked with Dr. Sengupta and his team in the past, with multiple published studies using MyoVista technology. This collaboration formalizes a multi-year arrangement with Rutgers, which we believe will significantly accelerate our product development pipeline of new ECG algorithms for front-line physicians and other healthcare providers. There are millions of ECGs conducted every week and this collaboration reaffirms HeartSciences’ position at the leading edge of bringing new clinical capabilities to the ECG."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HSCS:
- HeartSciences and Rutgers University Announce Multi-Year Collaboration to Develop AI-based ECG Algorithms
- HeartSciences to Participate at the Benchmark Discovery One-on-One Investor Conference on December 1, 2022
- HeartSciences’ MyoVista® Technology Used to Develop AI-ECG Algorithm to Identify Patients at High-Risk of Major Adverse Cardiovascular Events
- HeartSciences Granted European Patent for Proprietary Electrode and Cable Connections for Use with its AI-Based MyoVista® ECG
- HeartSciences Announces Major Milestone with the Issuance of CPT® Codes by the American Medical Association for ECG AI Analysis of Cardiac Dysfunction